Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed small index

Neuromuscular Blockade Reversal Agent clinical trials

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Neuromuscular Blockade Reversal Agent: 1 US clinical trial tracked, none currently recruiting.

Neuromuscular Blockade Reversal Agent is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. The most active sponsor is Beth Israel Deaconess Medical Center, running 1 of these trials.

Enrollment posture brief

Registry condition neuromuscular-blockade-reversal-agent

OPEN 0 | RECR 0% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Neuromuscular Blockade R (th…0%
Open-enrollment share among volume-matched conditions near Neuromuscular Blockade Reversal Agent

Neuromuscular Blockade Reversal Agent has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neuromuscular Blockade Reversal Agent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neuromuscular Blockade Reversal Agent is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

Named interventions

Most-linked intervention names on Neuromuscular Blockade Reversal Agent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist]) Drug
1 trials

US sites by state

Facility locations filed on Neuromuscular Blockade Reversal Agent trials. A trial with sites in several states counts in each.

Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neuromuscular Blockade Reversal Agent page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Neuromuscular Blockade Reversal Agent trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Beth Israel Deaconess Medical Center sponsors the most Neuromuscular Blockade Reversal Agent trials on record, review their full trial history before evaluating a specific study. See Beth Israel Deaconess Medical Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuromuscular Blockade Reversal Agent condition card totals 1 registered trials; most-linked intervention Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist]); top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.